Birandra K. K Sinha

Dr. Birandra K. K Sinha

Laboratory of Toxicology and Toxicokinetic, National Cancer Institute at National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
ABAnjali Bahot
Anjali Bahot
GSGopinath Sekar
Gopinath Sekar
MBMahima Bansode
Mahima Bansode
KKKratika Khunteta
Kratika Khunteta
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
In recent years, the emergence of cancer drug resistance has been one of the crucial tumor hallmarks that are supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters, and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often result in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores the use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

1 July 2016 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
AKAshutosh Kumar
Ashutosh Kumar
MEMarilyn Ehrenshaft
Marilyn Ehrenshaft
ETErik J. Tokar
Erik J. Tokar
RMRonald P. Mason
Ronald P. Mason
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha

1 December 2018 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
CBCarl D. Bortner
Carl D. Bortner
RMRonald P. Mason
Ronald P. Mason
RCRonald E. Cannon
Ronald E. Cannon

Verified
Journal Article
Open access
PDF file
MSMansaa Singh
Mansaa Singh
HAHasmiq Liba Arora
Hasmiq Liba Arora
RNRutuja Sunil Naik
Rutuja Sunil Naik
SJShravani Joshi
Shravani Joshi
KSKaveri Sonawane
Kaveri Sonawane
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
Cancer drug resistance occurs when cancer cells evade cell death following treatment with chemotherapy, radiation therapy, and targeted therapies. This resistance is often linked to the reprogramming of programmed cell death (PCD) pathways, allowing cancer cells to survive drug-induced stress. However, certain anticancer therapies, when combined with specific agents or inhibitors, can induce ferroptosis—a form of cell death driven by iron-dependent lipid peroxidation. Currently, extensive preclinical and clinical research is underway to investigate the molecular, cellular, and tissue-specific mechanisms underlying ferroptosis, with the goal of identifying strategies to overcome drug resistance in cancers unresponsive to conventional PCD pathways. By harnessing ferroptosis, cancer cells can be compelled to undergo lipid peroxidation-induced death, potentially improving therapeutic outcomes in patients with cancer. This short review aims to enhance the understanding of ferroptosis inducers in cancer therapy and stimulate further research into ferroptosis-based approaches for more effective clinical cancer treatment.

12 February 2013 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
SBSuchandra Bhattacharjee
Suchandra Bhattacharjee
SCSaurabh Chatterjee
Saurabh Chatterjee
JJJinJie Jiang
JinJie Jiang
AMAnn G. Motten
Ann G. Motten
RMRonald P. Mason
Ronald P. Mason

1 December 2013 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
AKAshutosh Kumar
Ashutosh Kumar
SBSuchandra Bhattacharjee
Suchandra Bhattacharjee
MEMichael G. Espey
Michael G. Espey
RMRonald P. Mason
Ronald P. Mason
Nitric oxide (⋅NO) was originally identified as an innate cytotoxin. However, in tumors it can enhance resistance to chemotherapy and exacerbate cancer progression. Our previous studies indicated that ⋅NO/⋅NO-derived species react with etoposide (VP-16) in vitro and form products that show significantly reduced activity toward HL60 cells and lipopolysaccharide (LPS)-induced macrophages. Here, we further confirm the hypothesis that ÷NO generation contributes to VP-16 resistance by examining interactions of ⋅NO with VP-16 in inducible nitric-oxide synthase (iNOS)–expressing human melanoma A375 cells. Inhibition of iNOS catalysis by N6-(1-iminoethyl)-l-lysine dihydrochloride (L-NIL) in human melanoma A375 cells reversed VP-16 resistance, leading to increased DNA damage and apoptosis. Furthermore, we found that coculturing A375 melanoma cells with LPS-induced macrophage RAW cells also significantly reduced VP-16 cytotoxicity and DNA damage in A375 cells. We also examined the interactions of ⋅NO with another topoisomerase active drug, Adriamycin, in A375 cells. In contrast, to VP-16, ⋅NO caused no significant modulation of cytotoxicity or Adriamycin-dependent apoptosis, suggesting that ⋅NO does not interact with Adriamycin. Our studies support the hypothesis that ⋅NO oxidative chemistry can detoxify VP-16 through direct nitrogen oxide radical attack. Our results provide insights into the pharmacology and anticancer mechanisms of VP-16 that may ultimately contribute to increased resistance, treatment failure, and induction of secondary leukemia in VP-16–treated patients.